Curated News
By: NewsRamp Editorial Staff
July 25, 2025
Nutriband Pioneers Abuse-Deterrent Opioid Patches to Combat Public Health Crisis
TLDR
- Nutriband Inc. is leading in abuse-deterrent drug delivery with AVERSA Fentanyl and Buprenorphine, offering investors a competitive edge in a market with potential sales up to $200 million.
- Nutriband's AVERSA technology integrates transdermal innovation with abuse-deterrent science, creating patches that prevent misuse and accidental exposure of potent drugs like fentanyl and buprenorphine.
- Nutriband's development of abuse-deterrent patches like AVERSA Fentanyl and Buprenorphine aims to significantly reduce opioid abuse and accidental exposure, enhancing public health safety.
- Discover Nutriband's groundbreaking AVERSA technology, transforming transdermal patches into safer alternatives by deterring abuse and misuse of powerful opioids.
Impact - Why it Matters
The development of abuse-deterrent opioid patches by Nutriband Inc. is a critical step forward in addressing the opioid epidemic, offering a safer alternative to traditional pain management solutions. This innovation not only has the potential to save lives by reducing the risk of abuse and accidental exposure but also represents a significant advancement in pharmaceutical technology. The impact of these products extends beyond healthcare, offering economic benefits through projected sales and contributing to the global effort to curb opioid misuse.
Summary
Nutriband Inc. (NASDAQ: NTRB) is making significant strides in the development of abuse-deterrent drug delivery systems, with its flagship products AVERSA Fentanyl and AVERSA Buprenorphine leading the charge. These innovative transdermal patches are designed to combat the abuse and misuse of opioids, addressing a critical public health crisis. AVERSA Fentanyl, potentially the first of its kind, could generate peak annual U.S. sales of $80 to $200 million, while AVERSA Buprenorphine is projected to achieve between $70 and $130 million. Nutriband's scalable platform and global patent protection efforts underscore its commitment to revolutionizing drug safety. For more details, visit https://ibn.fm/8PgtJ.
Nutriband's AVERSA technology represents a groundbreaking approach to preventing the abuse of transdermal patches, offering hope in the fight against opioid addiction. The company's dedication to innovation is further highlighted by its collaboration with BioMedWire, a leading communications platform in the biotechnology sector, ensuring widespread awareness of its advancements. Discover more about Nutriband's mission and products at www.Nutriband.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband Pioneers Abuse-Deterrent Opioid Patches to Combat Public Health Crisis
